Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001171843-25-002028
Filing Date
2025-04-04
Accepted
2025-04-04 16:22:10
Documents
18
Period of Report
2025-05-28

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT edsa20250326_def14a.htm   iXBRL DEF 14A 672365
6 proxy_01.jpg GRAPHIC 125500
7 proxy_02.jpg GRAPHIC 132967
  Complete submission text file 0001171843-25-002028.txt   1869700

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA edsa-20240930.xsd EX-101.SCH 4080
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE edsa-20240930_def.xml EX-101.DEF 1750
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE edsa-20240930_lab.xml EX-101.LAB 1775
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE edsa-20240930_pre.xml EX-101.PRE 714
20 EXTRACTED XBRL INSTANCE DOCUMENT edsa20250326_def14a_htm.xml XML 105484
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Filer) CIK: 0001540159 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37619 | Film No.: 25815056
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)